Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers ; volume:15 ; number:1 ; day:5 ; month:9 ; year:2018 ; pages:1-14 ; date:12.2018
Retrovirology ; 15, Heft 1 (5.9.2018), 1-14, 12.2018
- Urheber
-
Landais, Elise
- Beteiligte Personen und Organisationen
-
Moore, Penny L.
SpringerLink (Online service)
- DOI
-
10.1186/s12977-018-0443-0
- URN
-
urn:nbn:de:101:1-2018102400254532543411
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Landais, Elise
- Moore, Penny L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Broadly Neutralizing Antibodies for HIV Eradication
The expanding array of HIV broadly neutralizing antibodies
Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
Design clues from functional constraints and broadly neutralizing antibodies
Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies
Characterization of V1V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals
Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject
Broadly Neutralizing Antibodies for HIV Eradication
The expanding array of HIV broadly neutralizing antibodies
Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
Design clues from functional constraints and broadly neutralizing antibodies
Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies
Characterization of V1V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals
Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject
Broadly Neutralizing Antibodies for HIV Eradication
The expanding array of HIV broadly neutralizing antibodies
Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
Design clues from functional constraints and broadly neutralizing antibodies
Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing
Identification and characterization of broadly neutralizing antibodies targeting viral infections
Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies
Characterization of V1V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals